Long-Term Real-World Experience with Safinamide in Patients with Parkinson’s Disease
Anna Planas-Ballvé, Núria Caballol Pons, Alejandro Peral Quirós, Isabel Gómez Ruiz, Marta Balagué Marmaña, Alexander J. Velázquez Ballester, Dolors Lozano Moreno, Asunción Ávila Rivera · 2024
Read Long-Term Real-World Experience with Safinamide in Patients with Parkinson’s Disease by Anna Planas-Ballvé, Núria Caballol Pons, Alejandro Peral Quirós, Isabel Gómez Ruiz, Marta Balagué Marmaña, Alexander J. Velázquez Ballester, Dolors Lozano Moreno, Asunción Ávila Rivera (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11674920.txt.
Description
Anna Planas-Ballvé and co-authors report long-term, real-world experience with safinamide, an add-on drug for Parkinson's disease, at one movement disorders unit. Trials had shown the drug helps, but everyday practice over years tells more. The team reviewed 180 patients treated between 2016 and 2022.
After a median follow-up of forty months, only eight percent had stopped the drug, suggesting it is well tolerated. Among those who stayed on it, motor scores held steady. The daily dose of levodopa, the main Parkinson's drug, rose over the years, as expected as the disease advances. Doses of a drug class, dopamine agonists, did not climb. In patients who never needed agonists, motor scores were stable. The authors conclude that safinamide keeps working and stays tolerable in routine care over the long term. They present the study as a real-world check that should accompany trial evidence.
Catalog record
| CREATOR | Anna Planas-Ballvé, Núria Caballol Pons, Alejandro Peral Quirós, Isabel Gómez Ruiz, Marta Balagué Marmaña, Alexander J. Velázquez Ballester, Dolors Lozano Moreno, Asunción Ávila Rivera |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 17 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |